CartaBio

CartaBio, Inc., headquartered in Boston, USA, was founded by a team of senior industry experts with an AI + Bio dual background and renowned professors from top American universities. The team members mainly come from Johnson & Johnson, Harvard Medical School, Princeton University, and the University of Michigan. CartaBio owns the exclusive rights to the spatial omics technology platform: SAFE (scission-accelerated fluorophore exchange) technology platform. This platform is a new type of live-cell fluorescence imaging technology with spatiotemporal resolution, offering advantages such as high efficiency, speed, non-toxicity, accurate quantification, and low cost. It enables simultaneous longitudinal analysis of multiple biomarkers in living cells or tissues. Compared with the first-generation technology, the SAFE platform reduces cell count requirements by 100 times, cuts costs by 5 times, and improves detection efficiency from weeks to 1-2 days. Using this platform, the company can generate proprietary, differentiated cellular spatial datasets at a low cost and expand applications in diagnostic and testing fields.